Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ARET0321 | COG | A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma: A Groupwide Phase III Study | Pediatric CIRB | Available to Open | |
| ARET0331 | COG | Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma: A Phase III Limited Institution Study | Pediatric CIRB | Completed | |
| ARET0332 | COG | A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARET12P1 | COG | A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma | Pediatric CIRB | Available to Open | |
| ARET2121 | COG | Intravitreal Melphalan for Intraocular Retinoblastoma | Pediatric CIRB | Available to Open | |
| ARST0332 | COG | Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARST03P1 | COG | A Pilot Phase II Study for Children with Infantile Fibrosarcoma | Pediatric CIRB | Completed | |
| ARST0431 | COG | Intensive Multi-Agent Therapy; Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARST0531 | COG | Randomized Study of Vincristine; Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS): A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARST08P1 | COG | A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12; Anti-IGF-IR Monoclonal Antibody; IND #100947; NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Pilot Study | Pediatric CIRB | Completed |